Association of cystatin C with ischemia in patients with coronary heart disease

Clinical Cardiology

Volumn 32, Issue 11, 2009, Pages

  Deo, Rajat ^a,c   Shlipak, Michael G ^b   Ix, Joachim H ^d   Ali, Sadia ^b   Schiller, Nelson B ^b   Whooley, Mary A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary heart disease; Cystatin C; Inducible ischemia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYSTATIN C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTPATIENT; STRESS ECHOCARDIOGRAPHY; TREADMILL EXERCISE;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; CYSTATIN C; ECHOCARDIOGRAPHY, STRESS; EXERCISE TEST; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 73349101569     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20465     Document Type: Article

References (25)

1. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, et al.: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275-281.
2. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, et al.: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-980.
3. Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P: Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic SyndromeManagement in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation. 2002;105:2361-2366.
4. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Pinero G, et al.: Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the global registry of acute coronary events (GRACE). Heart. 2003;89:1003-1008.
5. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, et al.: Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002;90:1246-1249.
6. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, et al.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351: 1285-1295.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
8. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, et al.: Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142:497-505.
9. ShlipakMG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, et al.: Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005;45:268-271.
10. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, et al.: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl JMed. 2005;352:2049-2060.
11. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, et al.: Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342-2348.
12. Armstrong WF, Zoghbi WA: Stress echocardiography: Current methodology and clinical applications. J Am Coll Cardiol. 2005;45:1739-1747.
13. Senior R, Monaghan M, Becher H, Mayet J, Nihoyannopoulos P: Stress echocardiography for the diagnosis and risk stratification of patients with suspected or known coronary artery disease: Acritical appraisal. Supported by the British Society of Echocardiography. Heart. 2005;91:427-436.
14. Cortigiani L, Picano E, Coletta C, Chiarella F, Mathias W, et al.: Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting. Am Heart J. 2001;141:621-629.
15. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, et al.: Depressive symptoms and health-related quality of life: The Heart and Soul Study. JAMA. 2003;290:215-221.
16. CollE,Botey A, Alvarez L, Poch E, Quinto L, et al.: SerumcystatinC as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-34.
17. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, et al.: Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312-318.
18. Gokkusu CA, Ozden TA, Gul H, Yildiz A: Relationship between plasma cystatin C and creatinine in chronic renal diseases and Tx-transplant patients. Clin Biochem. 2004;37:94-97.
19. Curhan G: Cystatin C: A marker of renal function or something more? Clin Chem. 2005;51:293-294.
20. Koenig W, Twardella D, Brenner H, Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321-327.
21. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, et al.: Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359-1366.
22. Ablad B, Bjorkman JA, Gustafsson D, Hansson G, Ostlund-Lindqvist AM, et al.: The role of sympathetic activity in atherogenesis: effects of beta-blockade. Am Heart J. 1988;116:322-327.
23. Brehm BR, Bertsch D, von Fallois J, Wolf SC: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2000;36: S401-S403.
24. Rosenson RS, Brown AS: Statin use in acute coronary syndromes: Cellular mechanisms and clinical evidence. Curr Opin Lipidol. 2002;13:625-630.
25. Boyle JJ: Macrophage activation in atherosclerosis: Pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 2005;3: 63-68.